This was confirmed in an independent cohort of DLBCL patients using GDC data and in multivariate analysis, implying that SAMHD1 is an independent prognostic biomarker for outcomes in DLBCL patients. The gene discussed is SAMHD1; the disease is diffuse large B-cell lymphoma.